Aflac stock steadies as Japan Post trims stake and mixed Q2 2026 results shape outlook
Published on 08/28/2026 at 21:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Aflac Inc. (US0010551028) stock is trading close to $116.94 as of August 28, 2026, with the insurer valued at $58.45 billion and carrying a price-to-earnings ratio of 12.44 according to recent market data.
On August 26, 2026, a major shareholder executed a modest sale of 13,200 Aflac shares at a weighted average price of $117.35, with transaction prices ranging between $116.87 and $117.655 per share per an insider-trading report, while still indirectly holding more than 50.7 million Aflac shares. The insider-trading report on the Aflac share sale indicates that investors are monitoring ownership changes but that the shareholder continues to have a sizable position. This insider activity comes as Aflac recently reported second quarter 2026 financial results that showed slightly higher revenue but a minor earnings shortfall versus expectations, a combination that leaves the market weighing the balance between growth and profitability.
Insider sale and ownership structure
The insider filing dated August 26, 2026 describes the sale of 13,200 Aflac common shares for proceeds of $1,549,020 at a weighted average price of $117.35, with individual trade prices between $116.87 and $117.655, highlighting that the disposal represented only a fraction of the shareholder's total stake. Details on the Aflac insider share transaction note that after these trades the investor still indirectly holds 50,752,390 Aflac shares, underlining that the transaction was more of a portfolio adjustment than a strategic exit.
In parallel, several institutional investors have reported new or increased positions in Aflac during August 2026, with individual filings mentioning investments in the low- to mid-single-digit million-dollar range and highlighting that Aflac stock opened at $116.45 on the most recent trading session. An institutional investment filing mentioning Aflac price performance cites an opening price of $116.45 for Aflac shares and presents the company as having attracted new institutional capital, suggesting that despite one shareholder's partial sale, broader investor interest remains intact.
Mixed second quarter 2026 results and analyst stance
Recent coverage of Aflac's second quarter 2026 results points to a mixed picture, with adjusted earnings per share of $1.75 compared with a consensus expectation of $1.78, meaning the company missed forecasts by $0.03 per share, while delivering revenue of $4.12 billion against expectations of $4.11 billion, a small positive variance on the top line. Coverage of Aflac second quarter 2026 earnings metrics emphasizes that revenue came in slightly above forecasts by $0.01 billion even as earnings were $0.03 below the anticipated level, underscoring a trade-off between revenue resilience and a modest margin squeeze.
Additional data on Aflac's quarterly performance describe an earlier set of quarterly figures where earnings of $1.75 per share narrowly missed a consensus estimate of $1.76 and quarterly revenue of $4.22 billion declined 1 percent year over year, with a net margin of 26.91 percent and return on equity of 13.27 percent for that period. An institutional filing summarizing Aflac quarterly metrics notes that analysts as a group expect Aflac to post earnings of 7.04 per share for the current fiscal year and that the company declared a quarterly dividend of $0.61 per share, corresponding to an annualized payout of $2.44 and a yield of 2.1 percent based on prevailing prices.
Recent commentary also mentions that a research firm initiated coverage of Aflac with an underperform rating and a price target of $103.00, expressing concerns about the insurer's business in Japan and pointing to a slowdown in its core third-sector operations, even as other sources show that the average analyst opinion on Aflac equates to a hold rating with an average target price of $116.62. An overview of the consensus rating and Aflac average price target indicates that while some analysts take a more cautious stance with downside targets, the broader consensus sees Aflac as fairly valued around its current trading range, reinforcing that the stock neither commands an aggressive buy label nor faces a broad sell recommendation.
Dividend profile and valuation context
Aflac's dividend policy remains a key element of the investment case, with the company having recently declared a quarterly dividend of $0.61 per share that translates into a full-year payment of $2.44 and a forward dividend yield of 2.1 percent at prevailing share prices, according to filings summarizing its capital-return strategy. A filing detailing Aflac dividend and yield data further notes that the dividend payout ratio stands at 26.15 percent, suggesting that the insurer retains significant earnings capacity for reinvestment or additional capital returns while maintaining a consistent income stream for shareholders.
From a valuation perspective, the latest market snapshot indicates that Aflac shares trade at $116.94 with a market capitalization of $58.45 billion and a price-to-earnings ratio of 12.44, placing the stock in a moderate valuation band compared with many peers and reflecting the balance between stable cash flows and the growth constraints of a mature insurance franchise. A market snapshot showing Aflac's price, market cap and P/E highlights that institutional investors evaluating Aflac can frame the current valuation in relation to its steady dividend yield, historical profitability metrics and the recent minor earnings miss, with the share price still trading below the 1 year high level mentioned in earlier filings.
Representative product: supplemental health and accident coverage
Aflac is widely known for providing supplemental health insurance products that are designed to pay cash benefits directly to policyholders when they face specific medical events, and one representative offering is its accident insurance coverage, which helps cover out-of-pocket costs such as deductibles, copayments and non-reimbursed expenses linked to accidental injuries. This product fits into Aflac's broader strategy of offering protection that complements primary medical insurance, aiming to give individuals and families financial support when they experience unexpected health setbacks.
Aflac stock price and trading venue
Aflac stock trades on the New York Stock Exchange under the ticker AFL, and recent market data show the shares changing hands at $116.94 as of August 28, 2026, reflecting investor reassessment of the company's positioning after the insider sale and the release of mixed second quarter 2026 results.
Read more
Investor Relations
More on Aflac stock and company information
Fact box
Company: Aflac Inc.
ISIN: US0010551028
Ticker: AFL
Exchange: NYSE
Price (as of August 28, 2026): $116.94 USD
Market cap: $58.45 billion (as of August 28, 2026)
Sector / Industry: Financials / Insurance
Index membership: S&P 500
